3 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling? https://www.fool.com/investing/2024/03/13/does-this-1-new-threat-make-sarepta-therapeutics/?source=iedfolrf0000001 Mar 13, 2024 - The threat is still emerging, but it could be significant.
REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study https://www.zacks.com/stock/news/2236810/regenxbio-rgnx-soars-15-on-interim-data-from-dmd-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2236810 Mar 06, 2024 - Data from an early-stage study shows that treatment with REGENXBIO's (RGNX) investigational Duchenne therapy RGX-202 demonstrates early evidence of strength and motor function improvement.
Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More https://www.zacks.com/stock/news/2223529/biotech-stock-roundup-gild-amgn-bmy-s-q4-results-mor-up-on-nvs-deal-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2223529 Feb 08, 2024 - Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector.

Pages: 1

Page 1